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Rigid amphipathic fusion inhibitors (RAFIs) are lipophilic inverted-cone-shaped molecules thought to antagonize the mem-
brane curvature transitions that occur during virus-cell fusion and are broad-spectrum antivirals against enveloped viruses
(Broad-SAVE). Here, we show that RAFIs act like membrane-binding photosensitizers: their antiviral effect is dependent on
light and the generation of singlet oxygen (1O2), similar to the mechanistic paradigm established for LJ001, a chemically unre-
lated class of Broad-SAVE. Photosensitization of viral membranes is a common mechanism that underlies these Broad-SAVE.
Recently, a few broad-spectrum antivirals have been describedthat target enveloped virus entry (1–10). Antivirals that can
target the biophysical process of virus-cell membrane fusion itself,
rather than any particular viral protein, not only have the poten-
tial to be truly broad spectrum (against any enveloped virus) but
also will likely have a high barrier to resistance (11–14). Thus,
gaining a fuller mechanistic understanding of antiviral com-
pounds reported to target the virus-cell membrane fusion process
is essential for developing the potential of this exciting broad-
spectrum antiviral strategy.
We originally described a class of thiazolidine-based lipophilic
broad-spectrum antivirals against enveloped viruses (Broad-
SAVE) (e.g., LJ001) that target a late stage of virus-cell fusion at
the level of membrane merger (9). Follow-up studies indicated
that LJ001, our first generation of Broad-SAVE, and the oxazoli-
dine-based JL series of compounds, our second generation Broad-
SAVE, act as membrane-targeted photosensitizers: they generate
singlet oxygen (1O2) in the plane of the membrane, and
1O2-me-
diated lipid oxidation results in changes in the biophysical prop-
erties of the viral envelope that are not conducive to virus-cell
membrane fusion (8). The salient point is that at antiviral concen-
trations, 1O2-mediated lipid oxidation is not detrimental to met-
abolically active cell membranes. This is the key mechanistic par-
adigm that has never been explicitly stated and tested (15) until
our recent studies (8, 9).
Shortly after our original description of the membrane-tar-
geted broad-spectrum antiviral LJ001 (9), St. Vincent et al. de-
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FIG 1 dUY11 generates singlet oxygen (1O2). (A) Structure of dUY11 and its perylene core. (B) dUY11 was added to a solution of 9,10-dimethylanthracene (DMA) and
exposed to light. At 0.1, 1, 3, or 6 h, DMA conversion was detected by 1H-nuclear magnetic resonance (NMR) (DMA/oxiDMA  3.1 ppm:2.1 ppm [methyl peak]).
Reactions were performed in tetrahydrofuran (THF) using 1 equivalent of DMA and 0.5 equivalent of dUY11, and -tocopherol where applicable, under an O2
atmosphere. Where applicable, THF was purged with argon (Ar) by the freeze-thaw method before the reaction was performed under Ar atmosphere. Mean  standard
deviation (SD), n  2 independent measurements. *, P  0.05; ***, P  0.001, two-way analysis of variance (ANOVA) followed by a Bonferroni posttest for multiple
comparisons. (C) DMA conversion by 1O2 production in 3 mM POPC (a C9 monounsaturated model phospholipid) LUV. It should be noted that concentrations
indicated in POPC are the local concentration of dUY11 in the strict lipid bilayer volume, calculated as described in reference 25. 1O2 production was measured through
its effect on a fluorescent 1O2 chemical trap. DMA reacts selectively with
1O2 in membranes to form the nonfluorescent 9,10-endoperoxide (DMAO2). By monitoring
the disappearance of DMA’s fluorescence signal (excitation at 379 nm and emission at 432 nm), we were able to estimate the level of 1O2 in the membrane.
1O2-associated
fluorescence disappearance data were analyzed using the quenching sphere-of-action model, I0 ⁄ I  1  Ksv
* QeVNAQ, where Ksv
* is the apparent Stern-Volmer constant
(indicating the reduction of fluorescence by the conversion of DMA to DMAO2), V is the sphere-of-action volume (i.e., the sphere that surrounds the
chromophore within which the “quencher” can be considered to be in contact with the chromophore), and NA is Avogadro’s constant. Mean  SD, n  3
independent measurements.
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scribed another class of antiviral molecules termed rigid amphi-
pathic fusion inhibitors (RAFIs) that also inhibit a number of
enveloped viruses at the level of virus-cell fusion (6). Mechanistic
studies indicate that RAFIs have “remarkably similar properties”
to LJ001. However, the authors present evidence that these RAFIs
inhibit virus-cell fusion by stabilizing the positive curvature of
membranes by virtue of their molecular geometry: RAFIs are in-
verted-cone-shaped molecules with a large hydrophilic head
group attached to a rigid and planar hydrophobic moiety that
inserts into the membrane. Thus, RAFIs are thought to act like
similarly shaped lysophospholipids, which are known to impair
the critical positive-to-negative membrane transitions that occur
during virus-cell fusion (2, 7). Nevertheless, we noted that the
rigid and planar hydrophobic moiety present in all effective RAFIs
is a perylene group (Fig. 1A) (3, 6), which is a well-known fluo-
rescent lipid probe and photosensitizer (16–18).
We, and others, have previously questioned whether the nano-
molar potency and apparent irreversible antiviral activity of RAFIs
can be attributed entirely to their molecular geometry (11, 13).
Thus, we synthesized the exemplar RAFI compound, dUY11 (see
the supplemental material and Fig. 1A), and asked if dUY11 is a
photosensitizer and, if so, whether its ability to generate 1O2 does
contribute to its antiviral activity (13).
Indeed, dUY11 generated 1O2 in solution, as indicated by the
oxidation of the 1O2-specific trap 9,10-dimethylanthracene
(DMA) (8) (Fig. 1B). Anaerobic conditions (argon [Ar]) or addi-
tion of an antioxidant (-tocopherol) abrogated dUY11-induced
DMA oxidation, underscoring the specificity of these results.
DMA is lipophilic and highly fluorescent when intercalated into
membranes. DMA fluorescence quenching analysis upon oxida-
tion by dUY11 in 1-palmitoyl-2-oleoyl-sn-glycero-3-phospho-
choline (POPC) large unilamellar vesicles (LUV) further con-
firmed the ability of dUY11 to generate 1O2 in membranes (Fig.
1C) and established dUY11 as a type II photosensitizer (19).
Next, to determine if the photosensitizing properties of dUY11
contributed to its antiviral activity, we performed dose-response
experiments in the presence or absence of light, as previously de-
scribed (8). Human herpes simplex virus 1 (HSV-1), a virus ex-
tensively used to characterize the antiviral activity of RAFIs, was
preincubated with various concentrations of dUY11 for 30 min in
the absence of light and then either exposed to a white-light source
for an additional 10 min or not, before being used to infect Vero
cells. Infectivity analysis confirmed that dUY11 was as potent
against HSV-1 (0.2 nM 50% inhibitory concentration [IC50])
(Fig. 2A) and as nontoxic (1.5 mM 50% cytotoxic concentration
[CC50]) (data not shown) as previously reported (3, 6). However,
dUY11 showed a complete absence of antiviral activity when no
light was provided (Fig. 2A), even at concentrations 100-fold
above the reported IC50 for dUY11 (3, 6). Similar results were
obtained using various enveloped RNA viruses unrelated to
FIG 2 dUY11’s antiviral activity is dependent on light. (A) Dose-response of
dUY11 against HSV-1–GFP, in the presence (10 min) or absence of light,
analyzed by flow cytometry. Mean  SD, n  2 biological replicates. NA, not
active. (B) Antiviral activity of 1 M dUY11 against HSV-1–GFP, NDV-GFP,
VSV-Luc, and SeV-GFP in the presence (10 min) or absence of light, analyzed
by flow cytometry (GFP) or luciferase activity in cell lysates (Luc). Mean  SD,
n  2 biological replicates. Light versus no light: **, P  0.01; ***, P  0.001,
two-way ANOVA followed by a Bonferroni posttest for multiple comparisons.
(C) Dose-response antiviral activity (IC50) of dUY11 against NDV-GFP under
various times of light exposure (0, 5, and 30 min), analyzed by flow cytometry.
Mean  SD, n  2 biological replicates. IC50 values were calculated using
nonlinear regression analysis in GraphPad Prism. All data are presented as
relative percentages of infection normalized to mock-treated conditions (set as
100%). Five minutes versus 30 min of light exposure, P  0.0001, extra sum-
of-squares F-test.
FIG 3 dUY11’s antiviral activity is dependent on 1O2. Antiviral activity of 25
and 75 nM dUY11 in the absence (mock) or presence of 100 mM of the specific
1O2 quencher NaN3. (A) HSV-1–GFP; (B) NDV-GFP. Infection was analyzed
by flow cytometry, and data are presented as relative percentages of infection
normalized to percentages of GFP-positive cells observed under mock-treated
conditions (set as 100%).
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HSV-1 (a DNA virus), such as Newcastle disease virus (NDV),
Sendai virus (SeV), and vesicular stomatitis virus (VSV) (Fig. 2B),
confirming that the broad-spectrum antiviral activity of dUY11
against enveloped viruses is indeed light dependent. As a type II
photosensitizer, dUY11’s antiviral activity should be dependent
on both its concentration and the time of light exposure. Indeed,
using NDV-green fluorescent protein (GFP), we found that the
antiviral activity of dUY11 increased (lower IC50) as a function of
the time of light exposure (Fig. 2C), similar to what has been
described for LJ001 (8).
Finally, sodium azide (NaN3), a specific quencher of
1O2 (20),
reversed the antiviral activity of dUY11 against HSV-1 and NDV
(Fig. 3A and B, respectively). Note that the apparent potency of
dUY11 against both viruses was greater in experiment 2 (lower
IC50), concordant with the lesser degree of NaN3-mediated rever-
sal observed, especially at higher concentrations (75 nM) of
dUY11. In sum, our results confirm the specific involvement of
1O2 in dUY11’s broad-spectrum antiviral activity.
1O2-mediated lipid oxidation targets the CC double bonds in
unsaturated phospholipids and introduces polar hydroxylated
acyl chains in the middle of the hydrophobic membrane lipid
bilayer. Clustering of these oxidized phospholipids results in
decreased membrane fluidity, which negatively impacts on the
membrane’s ability to undergo the extreme membrane curva-
ture transitions occurring during virus-cell fusion (8, 21).
Thus, photosensitization of viral membranes requires the pres-
ence of unsaturated acyl chains and results in a decrease in
membrane fluidity or increased rigidity. To determine if dUY11
induced such biophysical changes in model membranes, we mea-
sured the fluorescence anisotropy of the 1,6-diphenyl-1,3,5-
hexatriene (DPH) probe after treatment of artificial membranes
with dUY11. In Fig. 4A, the dose-dependent increase in anisot-
ropy (rDPH), mediated by dUY11, reflected its effect on in-
creasing membrane rigidity (22). Furthermore, the anisotropy in-
crease was more prominent in unsaturated (POPC) than
saturated (dimyristoylphosphatidylcholine [DMPC]) phospho-
lipid LUV (Fig. 4A), consistent with the specific targeting of un-
saturated phospholipids by dUY11-induced 1O2. The latter was
confirmed by the addition of the 1O2 quencher NaN3, which
brought the anisotropy levels of dUY11-treated POPC LUV back
to the background levels observed with DMPC LUV (Fig. 4B).
Thus, we propose a mechanism of action for the exemplar
RAFI, dUY11, that is similar to the membrane-targeting photo-
sensitizers previously described as Broad-SAVE, such as LJ001 (9)
FIG 4 dUY11 increases membrane rigidity through generation of 1O2. (A) Effects of dUY11 on membrane rigidity measured by DPH fluorescence anisotropy
changes (rDPH), in saturated (DMPC) or unsaturated (POPC) phospholipid LUV, at 37°C. [dUY11]L (x axis) refers to the final concentration in the
membranes (lipid bilayer volume) (25). n  3 or 4 independent measurements. ****, P  0.0001, two-way ANOVA followed by a Bonferroni posttest for multiple
comparisons. (B) Effects of increasing concentrations of the 1O2 quencher NaN3 on the anisotropy value change induced by the addition of dUY11 to POPC LUV
at 37°C, [dUY11]L  264 nM (vertical dashed line in panel A). Horizontal dashed lines in panel B correspond to the rDPH values determined without NaN3,
in POPC and DMPC LUV. Anisotropy determinations were made at 37°C, far above the gel- to liquid-phase transition temperatures (Tm) of DMPC and POPC,
in order to guarantee that both lipid systems are in the liquid crystalline phase with similar DPH anisotropy values (	0.065  0.005). n  3 or 4 independent
measurements. *, P  0.05; **, P  0.01, one-way ANOVA followed by a Dunnett posttest for multiple comparisons versus the control column (NaN3  0 mM).
(C) Gbending can be defined in energy units, kBT (where kB is the Boltzmann’s constant and T the absolute temperature). This membrane bending force ranges
from 10 kBT (for highly fluid membranes, blue line) to 50 kBT (for less fluid membranes with 50% cholesterol, red line) (26, 27), the latter being similar to the
plasma membranes of mammalian cells. For any given membrane rigidity (blue, green, and red lines), note the exponential increase in absolute energy required
(kBT/nm
2) for bending membranes as the vesicle diameter gets smaller. The inset shows a specific simulation where a 5% increase in membrane rigidity (50¡55
kBT) on a 100-nm-sized vesicle (virion) results in at least a 3-log increase in energy required to reach the estimated diameter of the fusion stalk (10 nm). The actual
energy cost is likely much higher, as the model assumes bending from an initially flat membrane, whereas fusion requires bending from a positively curved to a
negatively curved membrane.
Photosensitizing Properties of dUY11
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and its oxazolidine counterparts (e.g., JL103, JL118, and JL122)
(8). Our model is consistent with all published data on RAFIs,
including those regarding membrane fluidity and lipid-phase
transitions of model membranes (3, 6). In contrast, the purely
geometric mechanism proposed by Schang and colleagues (stabi-
lization of positive curvature) (3, 6) cannot explain the light de-
pendency of dUY11’s antiviral activity or the reversal of its antivi-
ral activity by the 1O2 quencher NaN3. dUY11 (RAFIs) could very
well stabilize positive membrane curvature at high molar concen-
trations; however, this effect is unlikely to contribute to the anti-
viral effect seen at its nanomolar IC50.
Recently, Stachowiak and colleagues provided a lucid ac-
counting of the energetics involved in membrane curvature
(21). The energy cost per membrane area of creating a curved
sphere was estimated as Gbending  (8
)/(4
r
2), where  is the
bending rigidity of the membrane and r is the vesicle radius.
The bending rigidity ranges from 10 kBT for a highly fluid
membrane with unsaturated phospholipids to 50 kBT for
plasma (or plasma-like) membranes containing 50% choles-
terol, where kB is the Boltzmann’s constant and T the absolute
temperature. The bending energetics model suggests that even
a small increase in bending rigidity, when coupled to a large
decrease in vesicle radius (such as the diameter of the fusion
stalk during hemifusion), can result in an exponentially insur-
mountable amount of energy required to bend the membranes
for productive fusion to occur (Fig. 4C).
In conclusion, since all the active RAFIs described to date (3, 6)
possess a perylene core, it is likely that their antiviral activity is
effectuated through the photosensitizing mechanism of action
proposed for dUY11 (13). Our data underscore the generalizabil-
ity and relevance of our recently proposed mechanism of action
for Broad-SAVE that target the lipid component of membrane
fusion (8). Although the clinical potential of photoactivated mem-
brane-targeting Broad-SAVE appears limited by photophysical
hurdles, structure-activity relationship (SAR) studies that lever-
age advances in photochemistry and nanotechnology may over-
come these hurdles (23, 24). The unique mechanism of action of
these Broad-SAVE warrants further investigation.
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